How to Spot Fake Mounjaro or Zepbound: Warning Signs to Check

The clearest way to tell whether Mounjaro or Zepbound is real is to look at where it came from, not just what it looks like. Mounjaro and Zepbound are the only FDA-approved tirzepatide medicines, and Eli Lilly is the only lawful supplier of them in the United States ^[1]. Lilly states plainly that it never sells genuine Mounjaro or Zepbound on social media, so any pen or vial offered on Instagram, Facebook, Telegram, or WhatsApp is either fake or being resold by an individual — both of which Lilly calls unlawful and risky ^[1].

Beyond that, no single visual check can prove a pen is genuine. Counterfeiters copy packaging, and FDA has found fraudulently labeled compounded product in the US carrying pharmacy names that do not exist ^[7]. What you can do is compare the product against Lilly’s own published images, watch for the warning signs FDA lists, and buy only with a prescription filled at a state-licensed pharmacy ^[1][7]. Here is what the published record actually shows.

What counts as real tirzepatide in the US?

Mounjaro and Zepbound are the only two FDA-approved tirzepatide medicines, and Lilly is the only lawful supplier of FDA-approved tirzepatide ^[1]. Mounjaro is an injectable prescription medicine for adults with type 2 diabetes, used along with diet and exercise to improve blood sugar. Zepbound is an injectable prescription medicine that, used along with a reduced-calorie diet and increased physical activity, may help adults with obesity, or adults who are overweight with weight-related medical problems, lose weight and keep it off ^[1]. Both are approved only for people 18 and older ^[1].

Lilly states that it does not provide tirzepatide — the active ingredient in both drugs — to compounding pharmacies, med-spas, wellness centers, online retailers, or other manufacturers, and that it does not know where those sellers obtain the tirzepatide they sell ^[1]. Any product marketed simply as “tirzepatide,” rather than as Mounjaro or Zepbound, was not made by, studied by, or sold by Lilly and is not FDA-approved ^[1].

Lilly laid this out in an open letter published on June 20, 2024 ^[1][2].

Does Lilly ever sell Mounjaro or Zepbound on social media?

No. Lilly’s open letter states that it never sells genuine Mounjaro or Zepbound on social media, and that any Mounjaro or Zepbound offered for purchase on social media is unlawful — either fake or “resold” by an individual who obtained it some other way ^[1].

The National Association of Boards of Pharmacy (NABP) has reported that “illegal actors are taking advantage of high demand and short supply” of incretin medications “to sell substandard and falsified versions of these products to patients around the world” ^[1][2]. NABP has also identified thousands of websites promoting the illegal sale of GLP-1 agonists, including fake or unsafe versions of Mounjaro, Zepbound, and “tirzepatide” products ^[1].

FDA has determined that incretins, including Mounjaro and Zepbound, require a prescription and must be used under the supervision of a healthcare provider ^[1]. Any offer that skips the prescription step is a red flag on its face.

What should I check on the box and pen itself?

Lilly’s open letter includes a section titled “Identifying Genuine Lilly Products,” and the most reliable approach is to compare your pen and carton against the images Lilly itself publishes rather than against memory or a seller’s photos ^[1]. Lilly’s founder’s logo saying, which the company still invokes, is “If it bears a red Lilly, it’s right” ^[1].

A real-world counterfeit case shows what packaging comparison can catch. In Gurugram, India, authorities raided a vehicle on April 18 and seized fake Mounjaro injections worth ₹70 lakh, according to a report published in April 2026 ^[4]. Investigators compared the fake boxes against originals and found the counterfeit boxes came in different shades of blue and red, carried glaring typographical errors, and showed a pen illustration that was blurred, dark, and shorter than on the original ^[4]. The alleged mastermind, 32-year-old Avi Sharma, reportedly sourced raw materials from China through Alibaba, and injections were allegedly prepared by mixing water with raw drugs in a flat in Gurugram’s Sector 62 ^[4].

That case is from India, where Lilly launched Mounjaro in 2025 for both type 2 diabetes and obesity; in the US, by contrast, Mounjaro is approved for type 2 diabetes and Zepbound is the obesity indication ^[1][4]. But the tells are the same ones to check anywhere: print quality, color shades, spelling, and how the illustration compares with the manufacturer’s published images ^[1][4].

What has actually been found inside fake and compounded tirzepatide?

Lilly has tested compounded products advertised as tirzepatide and reported safety, sterility, and efficacy problems: bacteria, high impurity levels, a pink color instead of colorless, and in some samples a completely different chemical structure than its FDA-approved medicines. In at least one instance, the product was nothing more than sugar alcohol ^[1][2].

Lilly also warns that counterfeit products — ones advertised or designed to look like genuine Mounjaro or Zepbound — may contain no medicine, the wrong medicine, incorrect dosages, or multiple medicines mixed together. They may be made in unsanitary conditions, are not inspected by regulatory authorities, and are “never safe to use” ^[1][2].

More findings have continued to surface:

• On March 12, 2026, Lilly released a public letter reporting that its testing found significant levels of an impurity caused by a chemical reaction between tirzepatide and vitamin B12 in compounded products. The impurity was found in all 10 samples tested, and Lilly called for a nationwide recall of products containing both ingredients ^[5]. Lilly’s Chief Medical Officer David Hyman said compounded products are not reviewed for safety, effectiveness, or quality, and that adding a reactive substance like vitamin B12 without clinical testing or FDA review introduces additional unknown risks ^[5]. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, called the findings concerning but said Lilly had not disclosed enough detail about its sampling process to fully assess the risks ^[5].
• In Medina, Tennessee, the West Tennessee Drug Task Force raided a home and found more than 300 vials of counterfeit semaglutide, tirzepatide, and other weight-loss drugs, along with syringes, alcohol preps, and mailers, as reported on December 17, 2024. Some people who used the products reported rashes and injection pain, and officials said the supplier had allegedly also been feeding two med spas in the state ^[3].

Is a very low price a sign of a fake?

A deep discount is one of FDA’s listed red flags: medicine offered “at deep discounts or prices that seem too good to be true” is a warning sign when buying compounded GLP-1 drugs online ^[7].

The Tennessee case shows how price can be the first tip. The investigation began when a tipster reported unusually cheap weight-loss drugs: a 10-milligram vial of semaglutide sold for about $100, and a 15 mg vial for $140, while brand-name versions from Novo Nordisk sell for around $1,000 for a month’s supply ^[3].

Those specific figures are for semaglutide, not tirzepatide, and they come from one reported case — but the pattern is what matters. A price far below what the branded product normally costs is a reason to ask harder questions about where the product came from ^[3][7].

Lilly has announced that the Zepbound KwikPen is available at self-pay pricing at major pharmacies nationwide, in addition to LillyDirect ^[11]. No dollar figures are quoted here; compare any offer against the current price a licensed pharmacy or Lilly itself gives you before judging it.

What are FDA’s warning signs before you buy?

FDA’s guidance for consumers buying GLP-1 drugs online is to get a prescription from your doctor and fill it at a state-licensed pharmacy ^[7]. Beyond that, FDA lists these red flags ^[7]:

• Claims that the compounded drug is the same as an FDA-approved drug
• Deep discounts or prices that seem too good to be true
• Medicine that looks different from what you received at your local pharmacy before, or different from the website photo
• Packaging that is broken or damaged, or that lacks instructions for use
• No screening or prescription by a licensed doctor before the medicine is provided
• No licensed doctor available to answer questions after you receive it
• Spelling errors on the label or an incorrect pharmacy address
• A pharmacy name on the label you suspect is fraudulent

Injectable GLP-1 drugs require refrigeration. FDA recommends not using any injectable GLP-1 that arrives warm or with insufficient refrigeration, because heat can affect the drug’s quality ^[7].

FDA’s BeSafeRx campaign offers resources for safely buying prescription medicines online, including a “Locate a State-Licensed Online Pharmacy” lookup you can use to check whether an online pharmacy is state-licensed ^[7][8].

Does a pharmacy name on the label prove anything?

Not by itself. FDA is aware of fraudulent compounded semaglutide and tirzepatide marketed in the US that carries false label information ^[7]. In some cases, the compounding pharmacies named on the labels do not exist. In others, the label names a real licensed pharmacy that, based on information FDA gathered, did not compound the product ^[7][9].

FDA is aware of one reported adverse event tied to a product labeled as compounded tirzepatide from a pharmacy that did not actually make it. The report included redness, swelling, pain, and a red lump at the injection site ^[7].

A license lookup can tell you whether a pharmacy exists and is licensed — it cannot tell you what is inside the vial you were shipped ^[7][8].

Can pills, drops, or nasal sprays be real tirzepatide?

No. FDA has approved administration of tirzepatide only via under-the-skin injection ^[1][2]. Certain online pharmacies advertise compounded pill, under-the-tongue, nasal spray, and other oral versions of “tirzepatide,” but no regulator has evaluated the safety or effectiveness of any oral or nasal administration of tirzepatide ^[1][2].

If it is not an injectable, it is not an FDA-approved form of tirzepatide.

What about “research use only” peptide powder?

Lilly states that products labeled “research purposes only” or “not for human consumption” have not been purified to pharmaceutical-grade levels and are not appropriate for human use. People should never put them into their bodies ^[1].

FDA has also issued warning letters to active pharmaceutical ingredient distributors selling retatrutide and other GLP-1 drugs to compounders, and to telehealth companies marketing unapproved drugs such as retatrutide ^[7]. Retatrutide and cagrilintide cannot lawfully be used in compounding: they are not components of FDA-approved drugs and have not been found safe and effective for any condition ^[7].

On the import side, FDA has established a green list import alert (66-80) to stop GLP-1 active pharmaceutical ingredients with potential quality concerns from entering the US supply chain ^[7][9]. Separately, the US International Trade Commission instituted a Section 337 investigation in 2023 of products containing or purporting to contain tirzepatide ^[14][15].

What is the difference between counterfeit, compounded, and fraudulently labeled?

These three categories get mixed together, but they are not the same:

• Counterfeit products are advertised or designed to look like genuine Mounjaro or Zepbound. Lilly has identified such products and says it pursues legal remedies against those who falsely claim their products are Mounjaro, Zepbound, or “FDA-approved” tirzepatide ^[1][2].
• Compounded drugs are made by pharmacies and may be lawful in limited circumstances for individual patient needs, but they are never FDA-approved. FDA states that compounded drugs pose a higher risk to patients than FDA-approved drugs, and that it has “observed troubling conditions” during inspections of some compounding facilities — poor practices that can cause contamination and serious patient injury ^[1][2][7]. Compounders have argued their products are legal under a narrow federal provision that allows personalization, such as added vitamins or doses not available in the branded versions ^[5].
• Fraudulently labeled compounded product is the third category: real-looking vials that name pharmacies which did not make the contents, or pharmacies that do not exist at all ^[7].

FDA posts compounding inspections, recalls, Form 483s, warning letters, and state referral letters by facility name, and suggests searching “telehealth” in its Warning Letter Database ^[6]. FDA has also issued warning letters to 30 telehealth companies for making false or misleading claims about compounded weight-loss drugs ^[5].

What dosing and handling risks come with non-brand product?

If you do use a compounded multi-dose vial, FDA recommends discarding it within 28 days after first use, even if medication remains — even if the compounder’s instructions say it lasts longer — and using a new, sterile needle and syringe for every dose ^[7].

FDA has received multiple adverse event reports, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide, from patients measuring incorrect doses and in some cases health care professionals miscalculating them ^[7]. The agency has also received reports tied to doses beyond the approved label — more product per dose, more frequent dosing, or faster titration — with symptoms including nausea, vomiting, diarrhea, abdominal pain, and constipation ^[7].

The reported totals as of May 31, 2026:

Compounded drug	Adverse event reports to FDA
Compounded semaglutide	990
Compounded tirzepatide	more than 730

FDA notes these numbers are likely underreported, because state-licensed pharmacies that are not outsourcing facilities are not required to submit adverse events to the agency ^[7].

Two more cautions from the record: the salt forms semaglutide sodium and semaglutide acetate are different active ingredients from the approved drug, and FDA is aware of no lawful basis for their use in compounding ^[7]. And the Mounjaro and Zepbound labels carry a Boxed Warning regarding thyroid C-cell tumors ^[1].

What should I do if I think I have a fake?

Do not use any injectable GLP-1 product that arrived warm or with insufficient refrigeration ^[7]. If you have questions about the label or instructions for use, FDA suggests contacting the compounder or telehealth platform where you bought it, and talking to your doctor ^[7].

To report problems:

• Report unexpected experiences or side effects to FDA through MedWatch ^[8].
• Report websites you believe are illegally selling medicine through FDA’s online reporting form ^[8].
• Contact Lilly directly at 1-800-LillyRx (1-800-545-5979) ^[1]. Prescribers can chat with a Lilly Medical Professional through Lilly’s site ^[1].

Quick checklist before you inject

• Buy only with a prescription, filled at a state-licensed pharmacy you verified in the BeSafeRx lookup ^[7][8].
• Treat any brand-name Mounjaro or Zepbound offered on social media as unlawful — that is Lilly’s own statement ^[1].
• Compare the carton and pen against the manufacturer’s published images. Blurry printing, off-shade colors, or misspelled words mean stop ^[1][4][7].
• Check the solution. It should look the way it did before — Lilly found pink liquid where colorless was expected in compounded product ^[1].
• Refuse packages that lack instructions for use or arrive damaged or warm ^[7].
• Never use anything labeled “research purposes only” or “not for human consumption” ^[1].

If any single check fails, the safest move is to not inject and to ask a licensed clinician or pharmacist before proceeding.

Sources

1. Eli Lilly and Company. An open letter from Eli Lilly and Company regarding certain practices related to Mounjaro and Zepbound. June 20, 2024.
2. Eli Lilly and Company. Lilly warns patients about counterfeit and compounded medicines; releases open letter and takes further legal action against counterfeit, fake, unsafe, and untested products. June 20, 2024.
3. NBC News. Tennessee woman accused of selling fake weight loss drugs as counterfeit concerns grow.
4. The Economic Times. Different packaging, typos expose fake Mounjaro racket.
5. Reuters. Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks. March 12, 2026.
6. US Food and Drug Administration. Compounding: Inspections, recalls, and other actions.
7. US Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss.
8. US Food and Drug Administration. BeSafeRx: Your source for online pharmacy information.
9. Medical Daily. FDA screens GLP-1 ingredients at the border and warns of vials labeled with pharmacies that do not exist.
10. Eli Lilly and Company. Authentic Zepbound (tirzepatide) shipped to you. LillyDirect.
11. Eli Lilly and Company. Media statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect. March 16, 2026.
12. Lilly Medical. What are the health risks of using compounded tirzepatide?
13. Connecticut Office of the Attorney General. Letter to weight loss clinics and med spas regarding compounded GLP-1 weight loss medications. May 21, 2025.
14. United States International Trade Commission. USITC institutes Section 337 investigation of certain products containing tirzepatide and products purporting to contain tirzepatide. November 21, 2023.
15. Federal Register. Notice regarding certain products containing tirzepatide and products purporting to contain tirzepatide.
16. US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.